Fig. 1. SGK2 silencing sensitizes ovarian cancer cells to platinum treatment.

a Experimental design of the loss-of-function screening. Transduced cells were treated or not with CBDCA for 16 h using a dose able to induce only 10–20% of cell mortality. b SGK2 mRNA expression in the indicated EOC cell lines evaluated by qRT-PCR. c Western blot (WB) analyses evaluating SGK1, SGK2, and SGK3 expression in the indicated EOC cell lines. Vinculin was used as loading control. d Graph reports the viability of MDAH cells transduced with control (sh Ctrl) and three different SGK2 shRNAs, and then treated with CBDCA 140 µg/ml for 16 h as in a. On the right, WB analysis of SGK2, SGK1 and SGK3 expression in SGK2 silenced MDAH cells. e Graph reports the viability of OVCAR8 cells stably overexpressing EGFP-SGK2. Cells were treated with increasing doses of CBDCA and cell viability analyzed as in d. Results are expressed as percentage of CBDCA survived cells between treated and untreated cells (set as 100% as reference). On the right, WB analyses of SGK2 expression in the used cells. Vinculin was used as loading control. In d and e data represent the mean ± SD of three independent experiments. Significance was calculated using two-tailed, unpaired Student’s t test. ***p < 0.001, **p < 0.01, *p < 0.05. (See also Figs. S1 and S2).